G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib ...
Jack Bailey Johnw Umstead Drug Administration On Pepper Bio Inc Investor Relations Corporate Communications Therapeutics Inc
Source: wallstreet-online.de